Ngm Biopharmaceuticals Inc

NASDAQ:NGM   11:59:49 AM EDT
-0.37 (-1.67%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.69B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$22.65 Million
Adjusted EPS-$0.34
See more estimates
10-Day MA$22.58
50-Day MA$22.22
200-Day MA$24.81
See more pivots

Ngm Biopharmaceuticals Inc Stock, NASDAQ:NGM

333 Oyster Point Boulevard, South San Francisco, California 94080-7014
United States of America
Phone: +1.650.243.5555
Number of Employees: 210


NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases. Its lead product candidate, aldafermin, is designed for the treatment of patients with non-alcoholic steatohepatitis, with liver fibrosis stage 2, 3, or 4. The company was founded by Jin-Long Chen on December 20, 2007 and is headquartered in South San Francisco, CA.